/stocks — the workspaceLOADING
All UNCY SEC filings, by type → · Earnings date & implied move · Search inside filings
Unicycive Therapeutics, Inc. (UNCY) is a pharmaceutical preparations company. Piotroski F-Score 2/7. Next earnings projected around 2026-11-11 from UNCY's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind UNCY’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2023-12-31 vs 2022-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from UNCY’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on UNCY plus an auto-SWOT — built from UNCY's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate UNCY using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has UNCY been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as UNCY tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
The fair-value line is UNCY’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from UNCY’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
No lawmaker has disclosed a trade in UNCY under the STOCK Act.
Total return including reinvested dividends, from UNCY’s adjusted closing prices. Past return is not a forecast and not investment advice.
Projected from UNCY's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentUNCY files or announces.
UNCY has rallied after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much UNCY moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
UNCY has traded higher after most recent earnings releases.
A more typical earnings reaction has been approximately ±7.8%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-12 | +8.0% |
| 2026-05-12 | +7.0% |
| 2026-03-30 | +3.0% |
| 2025-11-12 | +11.3% |
| 2025-08-14 | +6.6% |
| 2025-05-14 | -9.1% |
| 2025-03-31 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -11.1% |
| 2024-11-13 | -7.5% |
None of the 5 estimators could run on UNCY's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for UNCY. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No sector peer set is priced for UNCY, so sector medians could not fill the gaps.
Every refusal recorded for UNCY → · How often we decline, and why →
No tracked institution reported a position in UNCY in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWM iShares Russell 2000 ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Only 2 of 5 tests could be computed from the filings — too few to summarise, so the individual results are shown without an overall label.
The score is passed over computable, not passed out of five. If only three tests could be run on UNCY’s filings, the score is out of three and the other two are listed with the reason they were skipped. Scoring a skipped test as a failure would punish a company for how its industry reports, and scoring it as a pass would flatter one.
Labels come from that ratio:
Below three computable tests we publish no label at all and show the individual results instead. A summary drawn from one or two tests is not a summary.
Free cash flow coverage carries the most weight in practice, because dividends are paid in cash and free cash flow is the cash actually available to pay them. The earnings payout ratio is the better-known test but the weaker one — earnings are an accounting figure, dividends are not. Where the two disagree, believe the cash.
Why tests get skipped. A REIT gets no earnings payout ratio: GAAP depreciation on appreciating property understates a REIT’s distributable earnings, which is exactly why the industry reports FFO and why REITs are required to distribute most of their taxable income. Banks and insurers get no leverage test, because deposits are debt and structurally high leverage is what a balance-sheet business is, not a warning sign.
The biggest limitation, stated plainly. The coverage tests read a single fiscal year, and one year of cash flow is far more volatile than a dividend record. A legal settlement, a tax payment or an acquisition can sink coverage in a year that says nothing about the dividend. Where a weak year contradicts a long unbroken record, we say so above rather than letting the harsher number stand alone — but you should still check what happened in that specific year.
The streak is the weakest test here, and it is deliberately listed last. Every dividend that was ever cut had an unbroken streak right up until the year it was cut. A freeze does not break the run — a company that holds its dividend flat through a bad year has not cut it — so raises are counted separately, and a long flat run cannot pass itself off as dividend growth.
Every figure above is from UNCY’s own SEC filings and the arithmetic is stated on this page. This describes what the filings show about the dividend’s coverage — it is not a prediction that the dividend will or will not be cut, not a recommendation, and not investment advice. A covered dividend can still be cut, and a strained one can still be maintained for years. Educational information only.
No open-market Form 4 buys or sells reported for UNCY in the last ~6 months.
2 of the 2 checks that ran found nothing new for UNCY. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Mountain View, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of Unicycive Therapeutics, Inc.’s 10-Q filed 2026-08-12, on EDGAR. Filings checked 2026-10-24. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works